CASI Pharmaceuticals, Inc.
CASIF · OTCMCIK 1962738fmd_1R8TGN1X4FSVKQRV2EM9ADP44PManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 6 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Rental revenue | 0 | 0 | 0 | 0 | 0 | – |
| Total revenues | 15 | 30 | 43 | 34 | 29 | 21 |
| Cost of revenue | 10 | 13 | 16 | 14 | 17 | 11 |
| Net interest income | 1 | 0 | 0 | 1 | – | – |
| Gross profit | 6 | 18 | 27 | 20 | 11 | 10 |
| Research and development | 11 | 14 | 16 | 10 | 9 | 6 |
| Selling, general and administrative | 27 | 38 | 38 | 42 | 41 | 47 |
| Operating income | (53) | (42) | (34) | (25) | (40) | (45) |
| Interest expense | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | 0 | 1 | 0 | 1 | 0 | 0 |
| Income before taxes | (48) | (36) | (37) | (26) | (38) | (46) |
| Income tax expense | 0 | 0 | 2 | (0) | 0 | – |
| Net income from continuing operations | (48) | (36) | (39) | (26) | (38) | – |
| Net income | (48) | (37) | (41) | (27) | (39) | (48) |